C&EN Webinar

Safety Considerations for the Development of Antibody-Drug Conjugates

Watch On Demand


On-demand virtual event


Biological & Medicinal Chemistry

Brought to you by:

Antibody-drug conjugates (ADCs) are a novel modality leveraging monoclonal antibody (mAb)-mediated delivery of a cytotoxic payload molecule to its target. Since the drug conjugated to mAb, typically a highly cytotoxic small molecule, can be released unconjugated in plasma and contribute to drug-drug interaction (DDI) potential, both the antibody and small molecule drug component are considered from the perspective of ADC safety.

Numerous chemotherapies utilizing ADCs are being developed for treatment of advanced cancers, however, the regulatory guidance for evaluation of ADC DDI potential is not well established.


Maciej Czerwinski, PhD

Director of Consulting


Catherine Dold

Health & Environment Writer, C&EN Media Group

ACS Institute

Keep learning. Excel in your career.

Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.